Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A4 | Q9H015 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9985141 | 1.00 | SLC22A4 (1.00) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL2215409 | 1.00 | SLC22A4 (1.00) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL175156 | 0.86 | SLC22A4 (0.76) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL12039657 | 0.86 | SLC22A4 (0.76) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL745229 | 0.86 | SLC22A4 (0.76) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL20925250 | 0.84 | SLC22A4 (0.72) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL20925187 | 0.82 | SLC22A4 (0.70) | SLC22A4POLBGAAKDM3BKMT2A | |
| SCHEMBL2217967 | 0.82 | SLC22A4 (0.69) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL28099455 | 0.80 | SLC22A4 (0.64) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL9604220 | 0.71 | SLC22A4 (0.55) | SLC22A4POLBGAAKDM3BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313534-B1 | SUPERABSORBENT POLYMERS AND STARCH POWDERS FOR USE IN SKIN CARE COMPOSITIONS | PROCTER & GAMBLE (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4662284-A1 | EPOXY-BASED UV-VIS-CURABLE ENCAPSULANT COMPOSITIONS | Sicpa Holding SA (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250302710-A1 | SKIN CARE COMPOSITIONS CONTAINING A RETINOID WITH REDUCED MALODOR | THE PROCTER & GAMBLE COMPANY | 2025-10-02 | — | — | US | disclosed |
| EP-4593786-A1 | STABLE SKIN CARE COMPOSITIONS CONTAINING A RETINOID | The Procter & Gamble Company (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-119923245-A | Stable skin care compositions comprising retinoids | 宝洁公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024255761-A1 | OLIGONUCLEOTIDE DELIVERY LIGAND COMPRISING SUGAR | 大睿生物 | 2024-12-19 | — | — | WO | disclosed |
| WO-2024165398-A1 | EPOXY-BASED UV-VIS-CURABLE ENCAPSULANT COMPOSITIONS | SICPA HOLDING SA (CH) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024073219-A1 | STABLE SKIN CARE COMPOSITIONS CONTAINING A RETINOID | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240099944-A1 | Stable Skin Care Compositions Containing a Retinoid | THE PROCTER & GAMBLE COMPANY | 2024-03-28 | — | — | US | disclosed |
| CN-115197126-A | Novel NMNAT enzyme agonist and preparation and application thereof | 清华大学 | 2022-10-18 | — | — | CN | disclosed |
| EP-2827835-B2 | SUPERABSORBENT POLYMERS AND SILICONE ELASTOMER FOR USE IN SKIN CARE COMPOSITIONS | PROCTER & GAMBLE (US) | 2022-09-07 | — | — | EP | disclosed |
| US-9918964-B2 | Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20110301180-A1 | Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration | STANFORD UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301180-A1 | Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration | PC, PFKP, UQCRC1 | SLC22A4 3741/4885POLB 853/4885ALPL 4604/4885 |
| US-20250302710-A1 | SKIN CARE COMPOSITIONS CONTAINING A RETINOID WITH REDUCED MALODOR | RBP4, RARA, RBP1 | SLC22A4 196/4885POLB 981/4885ALPL 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.